Group items tagged

Grundon Waste Management has introduced what it claims to be the UK's first verified nationwide inhaler return and recycling initiative. NHS Trusts and community pharmacies participating in the new scheme will have specialised recycling containers for inhalers installed to simplify public participation, Grundon said in a statement. Inhalers alone contribute to 4 per cent of NHS CO2 emissions, with around 73 million dispensed annually. By 2026, the health service aims to achieve a 50 per cent reduction in carbon emissions from waste management, a target that rises to 80 percent between 2028 and 2032, as outlined in the NHS Clinical Waste Strategy. "This scheme holds the potential to revolutionise the approach of NHS Trusts towards achieving heightened carbon savings and ultimately, net zero emissions," said Chris Edwards, Grundon's General Manager - Technical. "Each discarded pressurised Metered Dose Inhaler (pMDI) contains highly polluting hydrofluorocarbon (HFC) gases - a category of greenhouse gas known to be over a thousand times more detrimental than carbon dioxide in driving climate change." "This initiative securely captures these gases and repurposes them for application in the refrigeration sector. By also recycling the plastic and aluminium components of the device, we are making a noteworthy contribution to the circular economy," he added. Once collected, these will undergo processing at Grundon's specialist recycling facility in Ewelme, Oxfordshire, which is capable of handling more than 200,000 inhalers a day. The company aims to recycle 80 per cent of all prescribed inhalers by 2025, the statement added.

Global healthcare company Mundipharma and Vectura, an inhalation contract development and manufacturing organization, have entered into a collaboration agreement aimed at reformulating an asthma inhaler as part of their commitment to reducing the product's carbon footprint. The companies will be working together on incorporating an environmentally friendly propellant into the formulation of flutiform, a pressurised metered-dose inhaler (pMDI) used for asthma treatment, to achieve a near-zero-emissions product. Currently, the product uses the approved apaflurane hydrofluoroalkane 227 (HFA-227), a type of fluorinated greenhouse gas, as its propellant. The European Union's regulation on these types of greenhouse gases targets a two-thirds reduction in their usage and subsequent emissions by 2030. In a joint statement, companies revealed that work is already in progress to find an alternative to the HFA-227 gas. Yuri Martina, Chief Development and Medical Officer at Mundipharma, said: "This is the first step in our long-term plan to develop a near-zero-emissions asthma inhaler.

To reduce greenhouse gas emissions from improperly disposed inhalers, patients are being encouraged to return their used or expired inhalers to designated community pharmacies. A community pharmacy initiative in NHS Lothian has resulted in an impressive 300 per cent surge in the number of inhalers returned to community pharmacies for sustainable disposal. The initiative involved placing stickers on dispensing bags, encouraging patients to bring back their used inhalers to the pharmacy. Between February and May 2024, five community pharmacies in and around Edinburgh participated in this sustainability project and provided data. The data showed a significant increase in inhaler returns, with 20 inhalers being returned in the two weeks before the stickers were introduced, compared to 80 in the two weeks after the project concluded-a 300 per cent increase over the 10-week period.

NHS England has updated its 'Green plan guidance', outlining key actions for Integrated Care Boards (ICBs) and trusts to help achieve net zero carbon emissions. Among the recommended measures to reduce emissions from the medicines supply chain, organisations are asked to encourage patients to return used or expired inhalers to community pharmacies for appropriate disposal. Medicines account for approximately 25 per cent of NHS emissions, with a small number of medications contributing a large portion of this. For example, anaesthetic gases account for 2 per cent of NHS emissions, while inhalers contribute 3 per cent. The updated guidance says that organisations should build on ongoing progress in reducing these "point of use" emissions, while improving patient care and reducing waste. To address emissions from the medicines supply chain, the guidance recommends: Supporting high-quality, lower-carbon respiratory care Optimising inhaler choice by considering clinical appropriateness, the environmental impact of inhalers and patient preference Improving inhaler use and adherence Promoting the appropriate disposal of inhalers Addressing overprescribing and oversupply while ensuring support for patients in greatest need

To combat the effects of climate change, the Integrated Care System (ICS) in South East London (SEL) has initiated a pioneering inhaler recycling project. Supported by NHS England and spanning 20 community pharmacies across the region, the project marks the first nationally-funded pilot of its kind in England, targeting the reduction of greenhouse gas emissions from improperly disposed inhalers. The project, which commenced at King's College Hospital in February 2024, focuses on the recycling of pressurised metered-dose inhalers. These inhalers, due to their propellant content, contribute significantly to environmental harm, emitting gases equivalent to driving 71.8 miles in a standard petrol car.

If you have asthma, it's important to know when you should see a doctor about an asthma flare-up. A flare-up is a sudden increase in your symptoms, which can include coughing, wheezing, chest tightness, and shortness of breath. Flare-ups can be mild or severe, and they can occur at any time. If you're not sure whether you're having a flare-up, here are six obvious signs that it might be time to see a doctor. 1. YOU'RE USING YOUR INHALER MORE THAN USUAL If you have asthma, you likely have a rescue inhaler that you use when you're having symptoms. This inhaler contains a medication that can quickly relieve your symptoms. If you find that you're using your rescue inhaler more often than usual, it could be a sign that your asthma is getting worse and you need to see a doctor. By seeking a doctor near me online, you can find a reputable physician who will accurately diagnose and treat your asthma. Always look for a second opinion, as one doctor's opinion might differ from others. For example, some doctors might recommend that you use a daily inhaler, while others might only recommend using it when you're having symptoms.

Several pharmacies have joined the inhaler recycling scheme in Wolverhampton, West Midlands, to support NHS England's Greener NHS programme, which aims to achieve net zero emissions by 2040. It is part of a collaborative working initiative between the Royal Wolverhampton NHS Trust and AstraZeneca UK Ltd, supported by the Black Country Integrated Care Board and Wolverhampton City Local Pharmaceutical Committee. Under this scheme, old and used inhalers are recycled and transformed into new products, such as coat hangers and waste bins. Simon Evans, group chief strategy officer for The Royal Wolverhampton NHS Trust, emphasised the importance of prioritising the reduction of carbon footprint while maintaining high-quality care, to protect the planet for future generations. "The Trust has already made significant achievements in several areas including the physical estate, clinical services, waste recycling, catering and medicines - with this inhaler recycling scheme from pharmacy being the latest string to our bow," he said.

Vectura Fertin Pharma, an affiliate of Philip Morris International (PMI), has announced the sale of its subsidiary Vectura Group to global electronics major Molex Asia Holdings for £298 million. Vectura, based in Chippenham, UK, will be operated by Phillips Medisize, a Molex company and a leader in the design, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices. PMI, which acquired Vectura in 2021 amid strident opposition from health groups, has also announced the establishment of master service agreements to develop Vectura Fertin Pharma's inhaled therapeutics proprietary pipeline. The tobacco giant created Vectura Fertin Pharma as an autonomous unit, bringing together Vectura and Danish company Fertin Pharma, which it acquired in 2020, as part of its plan to go 'smoke-free' and switch to healthcare and wellness products. PMI, which fought off private equity firm Carlyle Group for the roughly 1-billion-pound buyout of Vectura, would receive an upfront cash consideration of £150 million, subject to customary purchase price adjustments, and potential deferred payments of up to £148 million.

Halothane is a time-tested inhalational anesthetic and is the gold standard for cost-effective induction and maintenance of anesthesia. It is manufactured by Piramal Critical Care in generic form for both human and veterinary use and is exported to 75 countries across the globe.

Piramal Critical Care is a business unit of Piramal Healthcare Limited. It manufactures and exports an extensive range of inhalation anesthetics like Sevoflurane, Halothane, Isoflurane and Enflurane, intravenous anesthetics like Propofol, regional anesthetics like Bupivacaine, muscle relaxants like Atracurium and plasma volume expanders like Polygeline.

Face masks can be quite discomforting to wear and there are a lot of reasons not to like them. You have to fiddle with the loops to wear them and after extended wear, they hurt. They also irritate your skin and fog up your glasses and make communication a little difficult. To foster mask adoption, the Department of Health and Human Services (HHS) in collaboration with the National Institute for Occupational Safety and Health (NIOSH) and the Biomedical Advanced Research and Development Authority, has launched a $500,000 "Mask Innovation Challenge" inviting Americans to submit ideas to make masks more comfortable to wear. The content is open until April 21 and participants have until then to submit innovative ideas that eliminate concerns with wearing masks while ensuring they are protecting themselves against coronavirus. In a press statement announcing the contest, Nikki Bratcher-Bowman, the acting assistant secretary for preparedness and response, said "with this mask challenge, we want to get people across the country involved in developing new masks that are both effective and comfortable. This will help us control COVID-19 and be better prepared for future public health emergencies." Contest Requirements and Prizes Anyone with a unique idea that follows CDC safety guidelines can submit their idea on or before 5 p.m ET on April 21. There are other requirements to enter and win this contest: 1. To receive a price, you must be a US citizen or a legal resident 2. For the first phase of the challenge, up to 10 winners will be chosen who will split a $100,000 prize, with each person taking $10,000 home. 3. Several parameters such as filtration efficiency, inhalation airflow resistance, fit, and other test methods will be used to judge the best design. According to HHS, sprays or drugs that can be inhaled or absorbed through the nose, mouth, or skin are not permitted to be used in mask design. NIOSH-approved respirators or FDA-approved surgical masks m

Olbas has announced the launch of its new TV ad campaign which will debut across the country this October. The TV campaign, which will be supported by a £1.5 million pound media investment, has been directed by commercial film director, Anthony Farquhar-Smith. The latest Olbas advertising creative will feature a new animated character, Lauren who is suffering with congestion caused by a cold. Lauren will be seen at home as the house begins to fill with balloons causing Lauren to feel uncomfortable and restricted, mimicking the 'bunged up' feeling of a heavy head cold. Olbas then saves the day as we see Lauren reach for a bottle of Olbas Oil to ease the symptoms of congestion, and as a result, the balloons deflate and the house returns to normal. Along with the large media investment, the campaign will also benefit from a strong PR programme to ensure the brand and retail sales are well supported throughout the peak cold and flu season. Owned by family-run health business, Lanes Health, Olbas Oil continues to be manufactured at their Gloucester based factory. Olbas uses only natural essential oils to provide a gentle but effective formulation to ease congestion and enhance breathing passages. The product offer includes Olbas Oil, Olbas For Children, Olbas Inhaler, Olbas Nasal Spray, Olbas Menthol Pastilles and Olbas Bath.

Piramal Critical Care manufactures generic and branded Enflurane (Compound 347) for Human use. Enflurane is the only modern Inhalation anesthetic approved for use in vaginal delivery. It is exported to various countries across the globe by Piramal Critical Care.

Isoflurane, USP is an inhalation anesthetic manufactured by Piramal Critical Care. It is used for induction and maintenance of general anesthesia in horses and dogs. Induction and recovery from anesthesia with isoflurane are rapid.

Manufactured by Piramal Critical Care, Sevoflurane is an inhalation anesthetic indicated for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgeries. It is manufactured in generic and branded form (Sojourn and Petrem) for both human and veterinary use.

Generic & Branded Isoflurane (Terrell and Attane) manufactured by Piramal Critical Care are used as inhalation anesthetics for human & veterinary use. It is used in induction and maintenance of general anesthesia. It is exported to more than 100 countries across the globe by Piramal Critical Care.

Manufactured by Piramal Critical Care, Petrem (Sevoflurane) is an inhalation anesthetic indicated for induction and maintenance of general anesthesia in dogs. It is the first generic sevoflurane approved for veterinary use.

Asthmatic inhalers have proved to be quite effective and successful in helping people control their asthmatic symptoms and attacks. Read below to learn more about the medications that are available for treating asthma.

The first category is pulmonary tuberculosis, which allows bacteria to spread easily from an infected person to a healthy person who inhales the infected air because of an infected person's coughing or sneezing.